Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Accumulated Expenses (2016 - 2025)

Ocular Therapeutix has reported Accumulated Expenses over the past 13 years, most recently at $43.8 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $43.8 million for Q4 2025, up 24.83% from a year ago — trailing twelve months through Dec 2025 was $43.8 million (up 24.83% YoY), and the annual figure for FY2025 was $43.8 million, up 24.83%.
  • Accumulated Expenses for Q4 2025 was $43.8 million at Ocular Therapeutix, up from $13.1 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for OCUL hit a ceiling of $43.8 million in Q4 2025 and a floor of $3.2 million in Q1 2021.
  • Median Accumulated Expenses over the past 5 years was $19.4 million (2021), compared with a mean of $19.0 million.
  • Biggest five-year swings in Accumulated Expenses: skyrocketed 524.8% in 2023 and later crashed 75.6% in 2024.
  • Ocular Therapeutix's Accumulated Expenses stood at $6.6 million in 2021, then soared by 265.27% to $24.1 million in 2022, then crashed by 66.15% to $8.2 million in 2023, then soared by 330.57% to $35.1 million in 2024, then increased by 24.83% to $43.8 million in 2025.
  • The last three reported values for Accumulated Expenses were $43.8 million (Q4 2025), $13.1 million (Q3 2025), and $34.4 million (Q2 2025) per Business Quant data.